Ipsen licenses ex-China rights to Simcere Zaiming’s SIM-0613

Dec. 22, 2025

Ipsen SA has signed an exclusive licensing agreement with Simcere Zaiming Pharmaceutical Co. Ltd. for global rights outside of Greater China for SIM-0613, an LRRC15-targeting antibody-drug conjugate developed by Simcere Zaiming for solid tumors. The program is expected to enter phase I development in the second half of next year.

BioWorld Science Deals and M&A License Cancer Antibody-drug conjugate Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for May 8, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 5, 2026

Rendering of a key measles protein targeted by neutralizing human antibodies

First measles treatment advances as vaccination rates drop

BioWorld

Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...

Hantavirus is ‘sentinel’ more than acute pandemic threat

BioWorld

News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...

The epidermal growth factor receptor in the inactive (left) and active (right) form.

Cytospire raises £61M series A to target EGFR in solid tumors

BioWorld

Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...